How could the PMPRB's 2025 Annual Report affect the Senate's oversight role?
The Senate receives the PMPRB's 2025 report on medicine prices and pharmaceutical trends The Patented Medicine Prices Review Board (PMPRB) tabled its 2025 Annual Report, which details trends in patented medicine prices and sales in Canada. This report, which covers sales of $24.4 billion and notes that Canadian list prices were third highest among the PMPRB11 countries, was formally submitted to the Clerks of the Senate. The Senate now receives this official document, allowing it to fulfill its formal oversight function regarding pharmaceutical trends and price protection.
- Effect
- Mixed
- How direct
- Stated in the reporting
- When
- Right away
- The story
- No new developments lately
How it reaches senate
-
The Patented Medicine Prices Review Board tabled its 2025 Annual Report, which reviews trends in the prices and sales of patented medicines in Canada. The report noted that sales of patented medicines reached $24.4 billion in 2025, representing 48% of all medicine sales in Canada. In 2025, 1,086 patented medicines for human use were reported to the board.
The full event1independent outlet -
The PMPRB formally submitted the 2025 Annual Report to the Clerks of the Senate, establishing the formal reporting structure for the board. This report provides updated information on the PMPRB’s price review and reporting activities in 2025. The Senate receives the report, which includes findings on spending on pharmaceutical research and development and notes that Canadian list prices ranked seventh highest among the 35 Organization for Economic Co-operation and Development (OECD) countries. This allows the Senate to perform its formal oversight of the PMPRB's mandate.
1 report connects these two. Brind only summarizes; follow a link to read the reporting itself.
- brantfordexpositor.ca Friday
-
type of legislative body, often the upper house or chamber of a bicameral legislature
Everything about senate
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- Sales of patented medicines in Canada were $24.4 billion in 2025.brantfordexpositor.ca
- Patented medicines accounted for 48% of the sales of all medicines in Canada in 2025.brantfordexpositor.ca
- Canadian list prices were third highest amongst the PMPRB11 countries.brantfordexpositor.ca
- Canadian prices ranked seventh highest among the 35 Organization for Economic Co-operation and Development (OECD) countries.brantfordexpositor.ca
Why it matters
The PMPRB's mandate is to protect Canadians from patent abuse related to excessive prices. The Senate's receipt of this detailed annual report allows it to monitor whether the PMPRB is effectively fulfilling its role in reviewing trends and ensuring price controls are adequate. The report highlights that Canada is the eighth largest national market for pharmaceuticals, representing 2.1% of worldwide sales in 2025.
This oversight is part of a broader legislative function, as the PMPRB operates under the formal reporting structure of the Senate. The findings on R&D expenditures, which reported $1.73 billion in 2025, also provide context on the balance between pharmaceutical innovation and consumer pricing within the Canadian market.
What we don't know yet
- What specific actions or recommendations does the PMPRB make within the 2025 Annual Report?
- How will the Senate utilize the data regarding Canadian prices ranking seventh highest among OECD countries?
Is this still moving?
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
What would change this answer
Who else could feel it
Other possible ripples from the same event.
Reporting
- brantfordexpositor.caFriday
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.